Eli Lilly restructuring US sales force
Eli Lilly announced a restructuring of its U.S. sales force this week as two money-making medications lose patent protection.
The Indianapolis-based pharmaceutical giant confirmed to WTHR that Lilly USA is making changes to its American sales force "to adapt to changing customer realities, evolutions in the health care environment and upcoming loss of exclusivity for two major products."
Lilly cited the patent expirations of Cymbalta in December 2013 and Evista in March 2014 as reasons for the restructuring.
The company also says its diabetes sales force is planning for the launches of two medicines.
The company says its bio-medicines sales force (which includes neuroscience, musculoskeletal, cardiovascular and men's health) will move to a smaller structure. It says it doesn't plan to disclose any numbers, although our partners at The Indianapolis Star report that less than 100 sales people in Indiana will be affected.
"It's also important to note that the impact to Indianapolis is minimal, and involves mostly structure and reporting changes," Lilly said in a statement.
In 2009, Lilly cut 5,500 jobs worldwide to streamline the company.